Lipocine Inc

For the period ended Dec 31, 2023. Filed Mar 7, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 7, 2024

LPCN$1.72+9.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. FORM 10-K SUMMARY

None

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Lipocine Inc.
	(Registrant)
Dated: March 7, 2024	/s/ Mahesh V. Patel
	Mahesh V. Patel, President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)
Dated: March 7, 2024	/s/ Krista Fogarty
	Krista Fogarty, Corporate Controller (Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

Krista Fogarty
Signature	Title	Date
/s/ Mahesh V. Patel	President and Chief Executive Officer (Principal Executive	March 7, 2024
Mahesh V. Patel	Officer and Principal Financial Officer)
/s/ Krista Fogarty	Corporate Controller (Principal Accounting Officer)	March 7, 2024
/s/ Jeffrey Fink	Director	March 7, 2024
Jeffrey Fink
/s/ Jill M. Jene	Director	March 7, 2024
Jill M. Jene

John Higuchi
/s/ John Higuchi	Director	March 7, 2024
/s/ R. Dana Ono	Director	March 7, 2024
R. Dana Ono
/s/ Spyros Papapetropoulos	Independent Lead Director and Chairman of the Board	March 7, 2024
Spyros Papapetropoulos

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.